Prof. Jinyi Xu is a professor of Medicinal Chemistry at China Pharmaceutical University. She earned her B.S. and Ph.D. from the same university and completed a postdoctoral fellowship at Kinki University, Japan. Her research focuses on the design and synthesis of novel drug candidates, natural product modification, and targeted protein degradation strategies like PROTACs and HyT. She has led over 10 major research projects, holds more than 40 patents, and has published over 200 peer-reviewed papers. Prof. Xu is also an Associate Editor of Bioorganic Chemistry and an active member of several national pharmaceutical committees.
-
Prof. Jinyi Xu obtained both her Bachelor of Science degree in Pharmacology in 1986 and her Doctorate in Medicinal Chemistry in 2001 from China Pharmaceutical University. Following her Ph.D., she pursued a postdoctoral fellowship at Kinki University in Japan, further strengthening her academic foundation in medicinal chemistry and drug discovery.
👨🏫Experience
-
Prof. Xu began her academic career at China Pharmaceutical University, where she was promoted to Associate Professor in 1999 and then to Full Professor in 2007. She currently serves as a Professor in the Department of Medicinal Chemistry, where she leads a dynamic research group as Principal Investigator. Her experience spans over three decades in medicinal chemistry, with an emphasis on natural product-based drug design and development.
🤝Awards and Honors
-
Prof. Xu has been recognized for her substantial contributions to pharmaceutical sciences in China. One of her most notable achievements includes the advancement of a candidate compound into Phase II clinical development. She is also an Associate Editor for the journal Bioorganic Chemistry, reflecting her standing in the global research community. Her significant participation as a committee member of the New Drug Evaluation Committee further demonstrates her influence in national drug assessment and development efforts.
💡Skills and Certifications
-
Prof. Xu brings extensive expertise in medicinal chemistry, natural product derivatization, structure-activity relationship (SAR) studies, and innovative drug design strategies. Her technical strengths lie in multi-target drug discovery, mechanism-based evaluation, and the translation of synthetic compounds into clinical drug candidates. She also possesses strong leadership and collaborative skills, evident through her ongoing partnerships with international researchers in the USA and UK, and her involvement in both academic and industry-led pharmaceutical innovation.
🔬Research Focus
-
Prof. Xu’s research is centered on the design and synthesis of novel drug candidates, structural modification of natural products, and the development of innovative therapeutic modalities such as PROTAC (proteolysis-targeting chimeras) and HyT (hydrophobic tagging) degraders. Her work particularly addresses therapeutic areas like hypertension, cancer, and Alzheimer’s disease. Her current research projects funded by the National Natural Science Foundation of China focus on degradation-based therapeutic strategies and prodrug design using bioorthogonal chemistry.
🌎Conclusion
-
Prof. Jinyi Xu is a role model for scientific excellence. Her exceptional contributions to medicinal chemistry and drug discovery make her a deserving recipient of the Research for Best Researcher Award. Her achievements not only reflect academic distinction but also drive real-world solutions to pressing medical challenges.
📖Publications
-
Novel agents derived from natural product β-elemene: A second round of design and synthesis to enhance antitumor properties
Authors: Liu Zhouyan, Li Tong, Gu Chenglei, Xu Jingyi, Chen Jichao
Journal: Bioorganic and Medicinal Chemistry, 2025
-
In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
Authors: Xie Shaowen, Zhu Jingjie, Peng Yihan, Su Zhigui, Xu Shengtao
Journal: Angewandte Chemie International Edition, 2025
-
Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation
Authors: Feng Dazhi, Liu Bo, Chen Zhiwei, Ai Jing, Zhang Hefeng
Journal: Journal of Biomolecular Structure and Dynamics, 2025
-
Design, synthesis, and biological evaluation of novel HPK1 inhibitors possessing 3-cyano-quinoline moiety
Authors: Chen Long, Zhang Baixue, Zhou Pijun, Yao Hong, Xu Jingyi
Journal: Bioorganic Chemistry, 2024
-
Palladium-Mediated Bioorthogonal System for Prodrug Activation of N-Benzylbenzamide-Containing Tubulin Polymerization Inhibitors for the Treatment of Solid Tumors
Authors: Li Jinlong, Zhang Tong, Wu Di, Xu Jingyi, Xu Shengtao
Journal: Journal of Medicinal Chemistry, 2024
hi